---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-032604"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2023-07-12T23:59:59+00:00"
generated_at: "2026-06-13T09:25:14.780908+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx appoints Howard Horn as CFO and EVP, Corporate Strategy effective Oct 16, 2023

## Summary
- Howard Horn appointed CFO and EVP, Corporate Strategy effective October 16, 2023.
- Base salary of $590,000/year, target bonus 50%, sign-on bonus of $60,000.
- Equity award with target value of $6 million: 50% options, 50% RSUs vesting over 4 years.
- Previously CFO at Vir Biotechnology (2017-2023) and held finance roles at Biogen.
- Will lead finance, accounting, corporate strategy, and investor relations at Ultragenyx.

## SEC filing metadata
- accession: 0000950170-23-032604
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2023-07-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017023032604/0000950170-23-032604-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017023032604/rare-20230712.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-032604
- JSON: https://secwatch.observer/filing/0000950170-23-032604.json
- Plain text: https://secwatch.observer/filing/0000950170-23-032604.txt

## Key facts
- Executive change
  Howard Horn was appointed as Chief Financial Officer and Executive Vice President, Corporate Strategy at Ultragenyx Pharmaceutical Inc..
  - Action: appointed
  - Role: Chief Financial Officer and Executive Vice President, Corporate Strategy
  source text: On July 12, 2023, Ultragenyx Pharmaceutical Inc. (the “Company”) announced that Howard Horn has been appointed as the Company’s Chief Financial Officer and Executive Vice President, Corporate Strategy, effective as of October 16, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017023032604/0000950170-23-032604-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.